Johnson & Johnson Terminates Phase 2b DUPLEX-AD Study of JNJ-95475939 Following Interim Efficacy Analysis
核心洞察
Johnson & Johnson terminated the Phase 2b DUPLEX-AD study of JNJ-95475939 (搜索) for moderate to severe atopic dermatitis (搜索) after a planned interim analysis showed the drug failed to meet prespecified efficacy criteria.
The investigational subcutaneous agent was well tolerated with no new safety signals, but did not achieve the level of efficacy required to justify further development in atopic dermatitis (搜索).
The study included dupilumab as an active comparator and evaluated EASI-75 response at week 12 as the primary endpoint, highlighting the challenge of demonstrating competitive benefit in the current treatment landscape.
Johnson & Johnson has terminated its Phase 2b DUPLEX-AD study evaluating JNJ-95475939 (搜索) for moderate to severe atopic dermatitis (搜索) following a planned interim analysis that failed to meet prespecified efficacy criteria. The decision underscores the ongoing challenges in developing new treatments for a disease where a significant proportion of patients experience inadequate disease control despite available targeted biologics and small molecules.
Study Design and Endpoints
The DUPLEX-AD study (NCT06881251) was a multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group, dose-ranging trial. Participants were randomized to one of five arms: an active comparator arm receiving dupilumab, three experimental arms receiving different dose regimens of JNJ-95475939 (搜索), and a placebo arm that crossed over to the investigational agent after week 10.
The primary endpoint was the proportion of participants achieving EASI-75 at week 12. Secondary endpoints included higher thresholds of skin clearance (EASI-90 and EASI-100), validated Investigator Global Assessment for AD (vIGA-AD) responses, percent change from baseline in EASI score, and multiple patient-reported outcomes assessing pruritus, skin pain, and sleep disturbance.
Efficacy Results Drive Termination Decision
According to Johnson & Johnson, JNJ-95475939 (搜索) did not achieve the level of efficacy required to justify further development in atopic dermatitis (搜索). While detailed efficacy data have not been publicly disclosed, the decision suggests that improvements in key endpoints such as EASI-75 at week 12 did not sufficiently differentiate the investigational agent from placebo or compare favorably with the active control.
The company stated that the results of the planned interim analysis "did not meet the high-bar efficacy we established for advancing our clinical development programs for atopic dermatitis (搜索)."
Safety Profile Remains Favorable
From a safety perspective, JNJ-95475939 (搜索) was reported to be generally well tolerated. No new safety signals emerged during the interim review, and adverse event monitoring did not identify safety concerns that contributed to the study's discontinuation. Johnson & Johnson confirmed that "JNJ-5939 was well tolerated in the study."
This distinction is clinically relevant, as the decision to halt development was driven by efficacy considerations rather than tolerability or risk profile.
Competitive Landscape Challenges
The inclusion of dupilumab as an active comparator reflects current expectations in atopic dermatitis (搜索) drug development. With established biologics demonstrating robust EASI and vIGA responses, investigational agents are increasingly evaluated against a higher efficacy benchmark. The DUPLEX-AD results highlight the challenge of demonstrating incremental or competitive benefit in an increasingly crowded treatment landscape.
Continued Commitment to Atopic Dermatitis Research
Despite this setback, Johnson & Johnson has reiterated its continued commitment to atopic dermatitis (搜索) research and development. The company stated it is "deeply committed to progressing our rich pipeline of clinical-stage and pre-clinical drug candidates for atopic dermatitis."
The company emphasized the significant unmet need in atopic dermatitis (搜索), noting that the chronic and often debilitating disease "places both physical and emotional burdens on patients and their families" and affects "more than 100 million individuals worldwide."
Johnson & Johnson indicated it looks forward to "delivering new, transformative medicines that have the greatest potential to meet the needs" of patients with this condition.